In a first for China, Neuracle’s implantable brain-computer interface wins approval

AI Summary
Neuracle Medical Technology has received China's first approval for an implantable brain-computer interface (BCI) system. The device aims to restore hand motor function in patients with spinal cord injuries. This regulatory milestone highlights China's growing neurotechnology sector, with domestic BCI companies emerging as potential competitors to firms like Neuralink. Neuracle's system, a coin-sized wireless device placed on the brain's surface, reads neural signals and translates them into hand movements. The approval marks the first time globally that an invasive BCI can be commercially sold and used on patients. Neuracle, which also develops scientific research equipment, recently began its listing process on the Shanghai Stock Exchange.
Key Entities & Roles
Keywords
Sentiment Analysis
Source Transparency
This article was automatically classified using rule-based analysis. The political bias score ranges from -1 (far left) to +1 (far right).
Topic Connections
Explore how the topics in this article connect to other news stories
Find Similar Articles
AI-PoweredDiscover articles with similar content using semantic similarity analysis.